Literature DB >> 11271079

Intravenous amiodarone in intensive care. Time for a reappraisal?

M Hughes1, A Binning.   

Abstract

Amiodarone is widely used in intensive care units for the treatment of a variety of arrhythmias. It is currently the drug of choice for supraventricular tachyarrhythmias in many units because of its combination of efficacy and safety. This review summarises the current state of knowledge regarding the short-term administration of intravenous amiodarone to control arrhythmias in perioperative, coronary care and intensive care patients. It outlines the electrophysiology, haemodynamics, pharmacokinetics and toxicity of the drug. In particular, it examines the recent concerns regarding acute pulmonary toxicity.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11271079     DOI： 10.1007/s001340000668

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


  9 in total

Review 1.  Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?

Authors:  Martin Schwaiblmair; Thomas Berghaus; Thomas Haeckel; Theodor Wagner; Wolfgang von Scheidt
Journal:  Clin Res Cardiol       Date:  2010-07-10       Impact factor: 5.460

Review 2.  Amiodarone: review of pulmonary effects and toxicity.

Authors:  Spyros A Papiris; Christina Triantafillidou; Likurgos Kolilekas; Despoina Markoulaki; Effrosyni D Manali
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

3.  High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study.

Authors:  Andreas J Mayr; Martin W Dünser; Nicole Ritsch; Werner Pajk; Barbara Friesenecker; Hans Knotzer; Hanno Ulmer; Volker Wenzel; Walter R Hasibeder
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

4.  Amiodarone-induced pulmonary toxicity.

Authors:  Desak Ketut Ernawati; Leanne Stafford; Jeffery David Hughes
Journal:  Br J Clin Pharmacol       Date:  2008-05-06       Impact factor: 4.335

Review 5.  Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical framework.

Authors:  Mengalvio E Sleeswijk; Trudeke Van Noord; Jaap E Tulleken; Jack J M Ligtenberg; Armand R J Girbes; Jan G Zijlstra
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

6.  Rapid onset of amiodarone induced pulmonary toxicity after lung lobe resection - A case report and review of recent literature.

Authors:  Heiko Baumann; Phillip Fichtenkamm; Thomas Schneider; Jürgen Biscoping; Michael Henrich
Journal:  Ann Med Surg (Lond)       Date:  2017-07-19

7.  Efficacy and safety of 1C class antiarrhythmic agent (propafenone) for supraventricular arrhythmias in septic shock compared to amiodarone: protocol of a prospective randomised double-blind study.

Authors:  Martin Balik; Petr Waldauf; Michal Maly; Vojtech Matousek; Tomas Brozek; Jan Rulisek; Michal Porizka; Robert Sachl; Michal Otahal; Petr Brestovansky; Eva Svobodova; Marek Flaksa; Zdenek Stach; Jaroslav Pazout; Frantisek Duska; Ondrej Smid; Martin Stritesky
Journal:  BMJ Open       Date:  2019-09-03       Impact factor: 2.692

8.  A Case Series of Vaping-Associated Lung Injury Requiring Mechanical Ventilation.

Authors:  June Choe; Peter Chen; Jeremy A Falk; Luan Nguyen; David Ng; Tanyalak Parimon; Sara Ghandehari
Journal:  Crit Care Explor       Date:  2020-01-29

9.  Cardiac arrhythmias in critically ill patients with coronavirus disease 2019: A retrospective population-based cohort study.

Authors:  Mik Wetterslev; Peter Karl Jacobsen; Christian Hassager; Christian Jøns; Niels Risum; Steen Pehrson; Anders Bastiansen; Anne Sofie Andreasen; Klaus Tjelle Kristiansen; Morten H Bestle; Thomas Mohr; Hasse Møller-Sørensen; Anders Perner
Journal:  Acta Anaesthesiol Scand       Date:  2021-03-13       Impact factor: 2.274
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.